Genetic diversity of human immunodeficiency virus-1 isolates in Paraná, Brazil

Brazilian Journal of Infectious Diseases

Volumn 14, Issue 3, 2010, Pages 230-236

  Toledo, Paula Virginia Michelon ^a   de Carvalho, Denise Siqueira ^a   de Rossi, Silvia Gomes ^a   Brindeiro, Rodrigo ^b   de Queiroz Telles, Flávio ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antiretroviral; Drug experienced patients; Genotype; HIV 1 subtypes

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE DERIVATIVE; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BRAZIL; CODON; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NONHUMAN; SEQUENCE ANALYSIS; SEX DIFFERENCE; TREATMENT DURATION; VIRUS EXAMINATION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 77957936019     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702010000300006     Document Type: Article

References (36)

1. Hahn BH, Shaw GM, Arya SK, Popovic M, Gallo RC, Wong-Staal F. Molecular cloning and characterization of the HTLVIII virus associated with AIDS. Nature 1984; 312(5990):166-9.
2. Robertson DL, Anderson JP, Bradac JA et al. HIV-1 nomenclature proposal. Science 2000; 288(5463):55-6.
3. Robertson DL, Sharp PM, McCutchan FE, Hahn BH. Recombination in HIV-1. Nature 1995; 374(6518):124-6.
4. Blackard JT, Cohen DE, Mayer KH. Human immunodefi ciency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin Infect Dis 2002; 34(8):1108-14.
5. Los Alamos National Laboratory. HIV Sequence database. [http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html] 2007.
6. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58:19-42.
7. Gonzales MJ, Machekano RN, Shafer RW. Human immunodefi ciency virus type 1 reverse-transcriptase and protease subtypes: classifi cation, amino acid mutation patterns, and prevalence in a Northern California clinic-based population. J Infect Dis 2001; 184(8):998-1006.
8. Wainberg M. HIV-1 subtype distribution and the problem of drug resistance. AIDS 2004; 18(Suppl 3):S63-S68.
9. Soares MA, De Oliveira T, Brindeiro RM et al. A specifi c subtype C of human immunodefi ciency virus type 1 circulates in Brazil. AIDS 2003; 17(1):11-21.
10. Soares EA, Santos RP, Pellegrini JA, Sprinz E, Tanuri A, Soares MA. Epidemiologic and molecular characterization of human immunodefi ciency virus type 1 in Southern Brazil. J Acquir Immune Defi c Syndr 2003; 34(5):520-6.
11. Soares EA, Martínez AM, Souza TM et al. HIV-1 subtype C dissemination in southern Brazil. AIDS 2005; 19(Suppl 4):S81-S86.
12. Soares EA, Santos AF, Sousa TM et al. Differential Drug Resistance Acquisition in HIV-1 of Subtypes B and C. PloS One 2007; 2(8):e730.
13. Ferreira JLP, Thomaz M, Rodrigues R et al. Molecular characterisation of newly identifi ed HIV-1 infections in Curitiba, Brazil: preponderance of clade C among males with recent infections. Mem Inst Oswaldo Cruz 2008; 103(8):800-8.
14. Brindeiro RM, Diaz RS, Sabino EC et al. Brazilian Network for Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS 2003; 17:1063-9.
15. Sabino EC, Shpaer EG, Morgado MG et al. Identifi cation of human immunodefi ciency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil. J Virol 1994; 68(10):6340-6.
16. Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG et al. Human immunodefi ciency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 2005; 100(1):73-8.
17. de Sa-Filho DJ, Soares MS, Candido V et al. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in Santos, Brazil. AIDS Res Hum Retroviruses 2008; 24(3):347-53.
18. Dumans AT, Barreto CC, Santos AF et al. Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virologic failure. Infect Genet Evol 2009; 9(1):62-70.
19. Kantor P, Katzenstein DA, Efron B et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2(4):e112.
20. Johnson A, Brun-Vezinet F, Clotet B et al. Update of the Drug Resistance Mutations in HIV-1: Spring 2008. Top HIV Med 2008; 16(1):62-8.
21. Alexander CS, Montessori B, Dong W et al. Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir Ther 2002; 7(1):31-5.
22. Frater AJ, Beardall A, Ariyoshi K et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001; 15(12):1493-502.
23. Bocket L, Cheret A, Deuffi c-Burban S et al. Impact of human immunodefi ciency virus type 1 subtype on fi rst-line antiretroviral therapy effectiveness. Antivir Ther 2005; 10(2):247-54.
24. Bannister WP, Ruiz L, Loveday C et al. EuroSIDA Study Group. HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther 2006; 11(6):707-15.
25. Champenois K, Deuffi c-Burban S, Cotte L et al. Natural polymorphisms in HIV-1 protease: impact on effectiveness of a fi rst-line lopinavir-containing antiretroviral therapy regimen. J Med Virol 2008; 80(11):1871-9.
26. Salemi M, de Oliveira T, Soares MA, Pybus O, Dumans AT et al. Different epidemic potentials of the HIV-1B and C subtypes. J Mol Evol 2005; 60:598-605.
27. Rhee SY, Fessel WJ, Zolopa AR et al. HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis 2005; 192(3):456-65.
28. Dumans AT, Soares MA, Machado ES et al. Synonymous genetic polymorphisms within Brazilian Human Immunodeficiency Virus Type 1 Subtypes may infl uence mutational routes to drug resistance. J Infect Dis 2004; 189:1232-8.
29. Cavalcanti AM, Lacerda HR, Brito AM, Pereira S, Medeiros D, Oliveira S. Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil. Mem Inst Oswaldo Cruz 2007; 102(7):785-92.
30. van de Vijver DA, Wensing AM, Angarano G et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defi c Syndr 2006; 41:352-60.
31. Caride E, Brindeiro R, Hertogs K et al. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodefi ciency virus type I found in Brazilian patients failing HAART. Virology 2000; 275:107-15.
32. Grossman Z, Istomin V, Averbuch D et al. Israel AIDS Multi-Center Study Group. Genetic variation at NNRTI resistanceassociated positions in patients infected with HIV-1 subtype C. AIDS 2004; 18(6):909-15.
33. Brenner B, Turner D, Oliveira M et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers crossresistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003, 17:F1-F5.
34. Lacerda HR, Medeiros LB, Cavalcanti AM, Ximenes RA, Albuquerque MF. Comparison of the epidemiology, profi le of mutations, and clinical response to antiretrovirals among subtypes B and F of the human immunodefi ciency virus type 1. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 102, n. 6, p. 693-9, 2007.
35. Caride E, Hertogs K, Larder B et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus genes 2001; 23(2):193-202.
36. Grossman Z, Paxinos EE, Averbuch D et al. Mutation D30N is not preferentially selected by human immunodefi ciency virus type 1 subtype C in the development of resistance to nelfi navir. Antimicrob Agents Chemother 2004; 48(6):2159-65.